Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

AZN

Astrazeneca plc ADR

Apr 19 • 04:00PM ET

68.55

Dollar change +0.19
Percentage change 0.28	%

Healthcare • Drug Manufacturers - General • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	NDX	P/E	35.92	EPS (ttm)	1.91	Insider Own	0.03%	Shs Outstand	3.10B	Perf Week	-0.55%
Market Cap	212.54B	Forward P/E	14.93	EPS next Y	4.59	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	4.29%
Income	5.96B	PEG	2.72	EPS next Q	0.96	Inst Own	15.96%	Short Float	0.25%	Perf Quarter	3.02%
Sales	45.81B	P/S	4.64	EPS this Y	11.44%	Inst Trans	-2.05%	Short Ratio	1.22	Perf Half Y	5.07%
Book/sh	12.63	P/B	5.43	EPS next Y	13.47%	ROA	6.03%	Short Interest	7.66M	Perf Year	-8.40%
Cash/sh	1.92	P/C	35.65	EPS next 5Y	13.20%	ROE	15.63%	52W Range	60.47 - 76.56	Perf YTD	1.78%
Dividend Est.	1.54 (2.25%)	P/FCF	22.92	EPS past 5Y	17.72%	ROI	9.55%	52W High	-10.46%	Beta	0.52
Dividend TTM	1.45 (2.12%)	Quick Ratio	0.64	Sales past 5Y	16.24%	Gross Margin	73.00%	52W Low	13.36%	ATR (14)	0.95
Dividend Ex-Date	Feb 22, 2024	Current Ratio	0.82	EPS Y/Y TTM	81.06%	Oper. Margin	16.21%	RSI (14)	58.36	Volatility	1.00% 1.24%
Employees	89900	Debt/Eq	0.73	Sales Y/Y TTM	3.29%	Profit Margin	13.00%	Recom	1.67	Target Price	77.76
Option/Short	Yes / Yes	LT Debt/Eq	0.59	EPS Q/Q	6.03%	Payout	73.87%	Rel Volume	0.75	Prev Close	68.36
Sales Surprise	-0.46%	EPS Surprise	-0.85%	Sales Q/Q	7.29%	Earnings	Apr 25 BMO	Avg Volume	6.28M	Price	68.55
SMA20	1.33%	SMA50	3.74%	SMA200	2.90%	Trades		Volume	4,735,554	Change	0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy	$75
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight
Apr-12-21	Downgrade	Argus	Buy → Hold

Show Previous Ratings

Apr-19-24 02:05PM	20 Countries with the Highest Cancer Survival Rates in the World (Insider Monkey)
Apr-18-24 11:45AM	Astrazeneca (AZN) Could Be a Great Choice (Zacks)
Apr-16-24 07:00AM	IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial (Business Wire)
Apr-14-24 08:10PM	PRESS DIGEST- Financial Times - April 15 (Reuters)
04:41AM	4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market (Motley Fool)
12:18PM	Loading…
Apr-13-24 12:18PM	Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024 (Insider Monkey)
09:00AM	Elon Musk's attack, Jamie Dimon's warnings, AstraZeneca CEO's big pay: Leadership news roundup (Quartz)
Apr-12-24 10:33AM	AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids (Zacks)
05:00AM	Moderna's new cancer vax, AstraZeneca CEO's big pay, and record-high drug shortages: Pharma news round up (Quartz)
Apr-11-24 06:15PM	Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know (Zacks)
01:53PM	AstraZeneca hit by investor backlash over chief Pascal Soriots £19m pay deal (The Telegraph)
01:32PM	World risks tepid Twenties as debt levels and inflation soar, warns IMF (The Telegraph)
01:01PM	AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition (Reuters)
12:53PM	UPDATE 2-AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition (Reuters)
12:37PM	AstraZeneca shareholders approve 2024 pay policy at AGM (Reuters)
09:15AM	Loading…
09:15AM	Biotech Innovations Paving the Way in Breast Cancer Fight (PR Newswire)
07:00AM	FASENRA approved for treatment of children aged 6 to 11 with severe asthma (Business Wire)
05:16AM	CORRECTED-UPDATE 1-European shares dip ahead of ECB policy decision (Reuters)
02:30AM	AstraZeneca announces dividend hike ahead of CEO pay vote (Reuters)
Apr-10-24 11:52AM	AstraZeneca's CEO makes double what Novo Nordisk's chief is paid. He needs a raise, some investors say (Quartz)
06:10AM	Major investors say AstraZeneca boss is massively underpaid on $21.5 million salary, despite earning more than double Novo Nordisks CEO (Fortune)
12:00AM	ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy? (TipRanks)
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
01:00AM	UK pharma companies told to make fewer drugs in draft net zero guidelines (The Telegraph)
Apr-08-24 12:34PM	AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor (Benzinga)
09:21AM	AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors (Zacks)
Apr-06-24 08:47PM	10 Best Weight Loss Drug Stocks to Buy Now (Insider Monkey)
Apr-05-24 11:10PM	ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (Business Wire)
09:43PM	ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors (Business Wire)
07:40PM	15 Most Densely Populated Cities in Europe (Insider Monkey)
05:50PM	Loading…
05:50PM	Astrazeneca (AZN) Advances But Underperforms Market: Key Facts (Zacks)
12:12PM	AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study (Zacks)
07:00AM	IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial (Business Wire)
06:16AM	Pioneering lung cancer drug offers hope for patients (The Telegraph)
03:01AM	UPDATE 2-AstraZeneca's Imfinzi improves survival in late-stage lung cancer trial (Reuters)
Apr-03-24 09:01AM	AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:48AM	Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio (Investopedia)
05:00AM	Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers (Reuters)
Apr-02-24 09:15AM	AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance (Zacks)
09:04AM	AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod (Zacks)
07:00AM	Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer (Business Wire)
Apr-01-24 06:00PM	Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
07:00AM	VOYDEYA approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH (Business Wire)
04:45AM	AstraZeneca gets FDA OK for rare disease drug acquired in Alexion buyout (BioPharma Dive)
Mar-29-24 11:04PM	20 Countries with the Highest Age Dependency Ratio in the World (Insider Monkey)
09:00AM	AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Mar-26-24 05:50PM	Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts (Zacks)
09:56AM	AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication (Zacks)
06:18AM	UPDATE 1-China to speed up 'new productive forces', vice president says (Reuters)
Mar-25-24 06:00PM	Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know (Zacks)
02:52PM	31 European Countries That Offer Citizenship by Descent (Insider Monkey)
09:48AM	German industry sceptical of China's vow to treat foreign firms equally (Reuters)
07:00AM	ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) (Business Wire)
Mar-23-24 05:00AM	Medicare is covering Wegovy, a new $4 million drug, and AstraZeneca bets $2 billion: pharma news round up (Quartz)
Mar-22-24 11:33AM	Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 07:17AM	UPDATE 2-Merck combination treatment for lung cancer fails late-stage study (Reuters)
Mar-20-24 05:58PM	UPDATE 1-GSK to cap out-of-pocket inhaler costs in US (Reuters)
05:51PM	15 Countries with the Highest Life Expectancy in Africa (Insider Monkey)
11:49AM	AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B (Zacks)
Mar-19-24 08:40PM	PRESS DIGEST-British Business - March 20 (Reuters)
08:39PM	PRESS DIGEST- Financial Times - March 20 (Reuters)
05:50PM	Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
04:28PM	These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, Fusion Pharmaceuticals, Nordstrom, International Paper, Tesla, and More (Barrons.com)
04:02PM	Fusion Rockets 99%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover (Investor's Business Daily)
01:46PM	AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US (Zacks)
01:24PM	AstraZeneca acquires Fusion Pharmaceuticals in $2B deal (Yahoo Finance Video)
12:40PM	These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, Fusion Pharmaceuticals, Nordstrom, International Paper, Tesla, and More (Barrons.com)
11:15AM	AstraZenca is betting $2 billion on next-gen cancer treatments (Quartz)
11:13AM	Fusion Pharmaceuticals Stock Soars. Its Being Acquired by AstraZeneca in $2.4 Billion Deal. (Barrons.com)
10:46AM	Super Micro, XPeng, AstraZeneca: Trending tickers (Yahoo Finance Video)
10:39AM	Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal (The Wall Street Journal)
09:03AM	Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover (Investor's Business Daily)
08:59AM	AstraZeneca signs agreement to acquire Fusion Pharmaceuticals (Pharmaceutical Business Review)
08:57AM	Stocks to Watch Tuesday: Unilever, Fusion Pharmaceuticals, Nvidia (The Wall Street Journal)
07:38AM	Fusion Pharmaceuticals Is Being Acquired by AstraZeneca in $2.4 Billion Deal. The Stock Is Soaring. (Barrons.com)
07:00AM	AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer (Business Wire)
06:53AM	AstraZeneca will cap the cost of its widely used inhalers at $35 a month (Quartz)
06:50AM	AstraZeneca snaps up rival to develop pioneering new cancer treatment (The Telegraph)
05:53AM	AstraZeneca melds with Fusion in $2B radiopharma buyout (FierceBiotech.com)
04:01AM	AstraZeneca buys into radiopharmaceuticals with $2.4B deal for Fusion Pharma (BioPharma Dive)
03:59AM	AstraZeneca Buys Fusion for Initial $2 Bln (The Wall Street Journal)
03:22AM	UPDATE 3-AstraZeneca bets on next-generation cancer therapy with $2 bln Fusion deal (Reuters)
03:10AM	AstraZeneca bets on next-generation cancer therapy with $2 billion Fusion deal (Reuters)
03:07AM	AstraZeneca to buy Fusion Pharma for $2 billion in cash (Reuters)
Mar-18-24 03:06PM	Now That Two Inhaler Makers Are Capping Patient Costs, Will More Follow? (The Wall Street Journal)
09:00AM	AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:14AM	AstraZeneca to cap out-of-pocket inhaler costs in US, following rival Boehringer's move (Reuters)
07:00AM	AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio (Business Wire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 12:26PM	AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline (Investopedia)
11:02AM	20 Countries That Spend the Most on Healthcare (Insider Monkey)
10:59AM	AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion (Zacks)
09:48AM	AstraZeneca inks $800M buyout of French biotech to snag phase 3 rare disease drug (FierceBiotech.com)
09:38AM	12 Most Profitable Biotech Stocks To Invest In (Insider Monkey)
07:07AM	AstraZeneca adds another rare disease drug in $800M buyout of startup Amolyt (BioPharma Dive)
03:45AM	UPDATE 2-AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio (Reuters)
03:15AM	AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare-disease portfolio (Reuters)
Mar-13-24 05:50PM	Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts (Zacks)
07:06AM	AstraZeneca announces initiation of THARROS a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD (Business Wire)
Mar-11-24 04:27AM	Reasons for the Decline of AstraZeneca PLC (AZN) in Q4 (Insider Monkey)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc ADR

Upgrade your FINVIZ experience